Abstract
Objectives To evaluate the transmission dynamics and health systems burden of COVID-19 with and without interventions, using an Agent Based Modeling (ABM) approach on a localized synthetic population.
Study design A synthetic population of Rangareddy district, Telangana state, India, with 5,48,323 agents and simulated using an ABM approach for three different scenarios.
Methods The patterns and trends of the COVID-19 in terms of infected, admitted, critical cases requiring intensive care and/ or ventilator support, mortality and recovery were examined. The model was simulated over a period of 365 days for a no lockdown scenario and two Non-Pharmaceutical Intervention (NPI) scenarios i.e., 50% lockdown and 75% lockdown scenarios. Sensitivity Analysis was performed to compare the effect of change of parameters on disease dynamics.
Results Results revealed that the peak values and slope of the curve declined as NPI became more stringent. The peak values could facilitate policymakers to plan the required capacity to accommodate influx of hospitalizations.
Conclusions ABM provides better insight into projections compared to compartmental models. The results could provide a platform for researchers and modelers to explore using ABM approach for COVID-19 projections with inclusion of interventions and health system preparedness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This is an unfunded research activity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NA
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.